Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2011

01-11-2011 | Epidemiology

Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses

Authors: Voralak Vichapat, Hans Garmo, Lars Holmberg, Ian S. Fentiman, Andrew Tutt, Cheryl Gillett, Margreet Lüchtenborg

Published in: Breast Cancer Research and Treatment | Issue 2/2011

Login to get access

Abstract

Studies comparing the prognosis after contralateral breast cancer (CBC) with that after unilateral breast cancer (UBC) shows conflicting results. We assessed the risk of breast cancer-specific death for women with metachronous CBC compared to those with a UBC in 8,478 women with invasive primary breast cancer registered in the Guy’s and St. Thomas’ Breast Cancer Tissue and Data Bank. Risk factors associated with breast cancer-specific death for women with CBC were estimated using Cox proportional hazards modelling. Prognoses after UBC and CBC were compared, with survival time for women with CBC calculated: (i) from CBC, (ii) from the initial cancer with CBC as a time-dependent covariate. Women diagnosed with CBC within 5 years after the initial primary breast cancer had a worse prognosis than those with CBC after 5 years and those with UBC. Women with CBC who had positive lymph nodes at the initial breast cancer diagnosis were at an increased risk of dying from breast cancer compared to those without [HR 2.5 (95% CI 1.5–4.0)]. For all stages of the initial breast cancer, a worse prognosis was observed after CBC. CBC increased the hazard originating from the initial cancer at any follow-up time, but the highest hazards were associated with a short interval to CBC. Metachronous CBC adds to the risk of dying from breast cancer. The risk increases substantially when it occurs shortly after the initial cancer, indicating a CBC in some instances may be an indicator of active distant disease. The occurrence of CBC implies a new surveillance and therapeutic situation.
Literature
1.
go back to reference Alexander AI, Mercer RJ, Muir IM, Mason B, Holdaway I (1989) Predicting survival in bilateral breast carcinoma. Aust N Z J Surg 59:35–37PubMedCrossRef Alexander AI, Mercer RJ, Muir IM, Mason B, Holdaway I (1989) Predicting survival in bilateral breast carcinoma. Aust N Z J Surg 59:35–37PubMedCrossRef
4.
go back to reference Beinart G, Gonzalez-Angulo AM, Broglio K, Mejia J, Ruggeri A, Mininberg E, Hortobagyi GN, Valero V (2007) Clinical course of 771 patients with bilateral breast cancer: characteristics associated with overall and recurrence-free survival. Clin Breast Cancer 7:867–874PubMedCrossRef Beinart G, Gonzalez-Angulo AM, Broglio K, Mejia J, Ruggeri A, Mininberg E, Hortobagyi GN, Valero V (2007) Clinical course of 771 patients with bilateral breast cancer: characteristics associated with overall and recurrence-free survival. Clin Breast Cancer 7:867–874PubMedCrossRef
5.
go back to reference Brenner H, Engelsmann B, Stegmaier C, Ziegler H (1993) Clinical epidemiology of bilateral breast cancer. Cancer 72:3629–3635PubMedCrossRef Brenner H, Engelsmann B, Stegmaier C, Ziegler H (1993) Clinical epidemiology of bilateral breast cancer. Cancer 72:3629–3635PubMedCrossRef
6.
go back to reference Broet P, De la Rochefordiere A, Scholl SM, Fourquet A, De Rycke Y, Pouillart P, Mosseri V, Asselain B (1999) Analyzing prognostic factors in breast cancer using a multistate model. Breast Cancer Res Treat 54:83–89PubMedCrossRef Broet P, De la Rochefordiere A, Scholl SM, Fourquet A, De Rycke Y, Pouillart P, Mosseri V, Asselain B (1999) Analyzing prognostic factors in breast cancer using a multistate model. Breast Cancer Res Treat 54:83–89PubMedCrossRef
7.
go back to reference Burns PE, Dabbs K, May C, Lees AW, Birkett LR, Jenkins HJ, Hanson J (1984) Bilateral breast cancer in northern Alberta: risk factors and survival patterns. Can Med Assoc J 130:881–886PubMed Burns PE, Dabbs K, May C, Lees AW, Birkett LR, Jenkins HJ, Hanson J (1984) Bilateral breast cancer in northern Alberta: risk factors and survival patterns. Can Med Assoc J 130:881–886PubMed
8.
go back to reference Carmichael AR, Bendall S, Lockerbie L, Prescott R, Bates T (2002) The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. Eur J Surg Oncol 28:388–391PubMedCrossRef Carmichael AR, Bendall S, Lockerbie L, Prescott R, Bates T (2002) The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. Eur J Surg Oncol 28:388–391PubMedCrossRef
11.
go back to reference Fisher ER, Fisher B, Sass R, Wickerham L (1984) Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4). XI. Bilateral breast cancer. Cancer 54:3002–3011PubMedCrossRef Fisher ER, Fisher B, Sass R, Wickerham L (1984) Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4). XI. Bilateral breast cancer. Cancer 54:3002–3011PubMedCrossRef
13.
go back to reference Fung MC, Schultz DJ, Solin LJ (1997) Early-stage bilateral breast cancer treated with breast-conserving surgery and definitive irradiation: the University of Pennsylvania experience. Int J Radiat Oncol Biol Phys 38:959–967PubMedCrossRef Fung MC, Schultz DJ, Solin LJ (1997) Early-stage bilateral breast cancer treated with breast-conserving surgery and definitive irradiation: the University of Pennsylvania experience. Int J Radiat Oncol Biol Phys 38:959–967PubMedCrossRef
14.
go back to reference Haagensen CD (1986) Diseases of the breast. Saunders, Philadelphia, London Haagensen CD (1986) Diseases of the breast. Saunders, Philadelphia, London
16.
go back to reference Healey EA, Cook EF, Orav EJ, Schnitt SJ, Connolly JL, Harris JR (1993) Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol 11:1545–1552PubMed Healey EA, Cook EF, Orav EJ, Schnitt SJ, Connolly JL, Harris JR (1993) Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol 11:1545–1552PubMed
18.
go back to reference Holmberg L, Adami HO, Ekbom A, Bergstrom R, Sandstrom A, Lindgren A (1988) Prognosis in bilateral breast cancer. Effects of time interval between first and second primary tumours. Br J Cancer 58:191–194PubMedCrossRef Holmberg L, Adami HO, Ekbom A, Bergstrom R, Sandstrom A, Lindgren A (1988) Prognosis in bilateral breast cancer. Effects of time interval between first and second primary tumours. Br J Cancer 58:191–194PubMedCrossRef
19.
go back to reference Kuo WH, Yen AM, Lee PH, Chen KM, Wang J, Chang KJ, Chen TH, Tsau HS (2009) Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. Br J Cancer 100:563–570. doi:10.1038/sj.bjc.6604898 PubMedCrossRef Kuo WH, Yen AM, Lee PH, Chen KM, Wang J, Chang KJ, Chen TH, Tsau HS (2009) Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. Br J Cancer 100:563–570. doi:10.​1038/​sj.​bjc.​6604898 PubMedCrossRef
20.
go back to reference Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, Kliewer EV, Tonita JM, Kee-Seng C, Pompe-Kirn V, Martos C, Jonasson JG, Boffetta P, Brennan P (2006) Risk of second cancer among women with breast cancer. Int J Cancer 118:2285–2292. doi:10.1002/ijc.21651 PubMedCrossRef Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, Kliewer EV, Tonita JM, Kee-Seng C, Pompe-Kirn V, Martos C, Jonasson JG, Boffetta P, Brennan P (2006) Risk of second cancer among women with breast cancer. Int J Cancer 118:2285–2292. doi:10.​1002/​ijc.​21651 PubMedCrossRef
21.
go back to reference Mose S, Adamietz IA, Thilmann C, Saran F, Bernhard M, Pahnke R, Bottcher HD (1997) Bilateral breast carcinoma versus unilateral disease. Review of 498 patients. Am J Clin Oncol 20:541–545PubMedCrossRef Mose S, Adamietz IA, Thilmann C, Saran F, Bernhard M, Pahnke R, Bottcher HD (1997) Bilateral breast carcinoma versus unilateral disease. Review of 498 patients. Am J Clin Oncol 20:541–545PubMedCrossRef
23.
go back to reference Nout RA, Fiets WE, Struikmans H, Rosendaal FR, Putter H, Nortier JW (2008) The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer. Breast Cancer Res Treat 109:567–572. doi:10.1007/s10549-007-9681-x PubMedCrossRef Nout RA, Fiets WE, Struikmans H, Rosendaal FR, Putter H, Nortier JW (2008) The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer. Breast Cancer Res Treat 109:567–572. doi:10.​1007/​s10549-007-9681-x PubMedCrossRef
25.
go back to reference Robbins GF, Berg JW (1964) Bilateral primary breast cancer; a prospective clinicopathological study. Cancer 17:1501–1527PubMedCrossRef Robbins GF, Berg JW (1964) Bilateral primary breast cancer; a prospective clinicopathological study. Cancer 17:1501–1527PubMedCrossRef
26.
go back to reference Robinson E, Rennert G, Rennert HS, Neugut AI (1993) Survival of first and second primary breast cancer. Cancer 71:172–176PubMedCrossRef Robinson E, Rennert G, Rennert HS, Neugut AI (1993) Survival of first and second primary breast cancer. Cancer 71:172–176PubMedCrossRef
28.
go back to reference Schaapveld M, Visser O, Louwman WJ, Willemse PH, de Vries EG, van der Graaf WT, Otter R, Coebergh JW, van Leeuwen FE (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110:189–197. doi:10.1007/s10549-007-9709-2 PubMedCrossRef Schaapveld M, Visser O, Louwman WJ, Willemse PH, de Vries EG, van der Graaf WT, Otter R, Coebergh JW, van Leeuwen FE (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110:189–197. doi:10.​1007/​s10549-007-9709-2 PubMedCrossRef
30.
go back to reference Verkooijen HM, Chatelain V, Fioretta G, Vlastos G, Rapiti E, Sappino AP, Bouchardy C, Chappuis PO (2007) Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Res Treat 105:347–357. doi:10.1007/s10549-006-9455-x PubMedCrossRef Verkooijen HM, Chatelain V, Fioretta G, Vlastos G, Rapiti E, Sappino AP, Bouchardy C, Chappuis PO (2007) Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Res Treat 105:347–357. doi:10.​1007/​s10549-006-9455-x PubMedCrossRef
31.
go back to reference Vigano A, Bruera E, Jhangri GS, Newman SC, Fields AL, Suarez-Almazor ME (2000) Clinical survival predictors in patients with advanced cancer. Arch Intern Med 160:861–868PubMedCrossRef Vigano A, Bruera E, Jhangri GS, Newman SC, Fields AL, Suarez-Almazor ME (2000) Clinical survival predictors in patients with advanced cancer. Arch Intern Med 160:861–868PubMedCrossRef
32.
go back to reference von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J (2000) Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18:574–583 von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J (2000) Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18:574–583
Metadata
Title
Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses
Authors
Voralak Vichapat
Hans Garmo
Lars Holmberg
Ian S. Fentiman
Andrew Tutt
Cheryl Gillett
Margreet Lüchtenborg
Publication date
01-11-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1618-8

Other articles of this Issue 2/2011

Breast Cancer Research and Treatment 2/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine